Despite over 50 yr of experience with steroid replacementtherapy, the management of congenital adrenal hyperplasia(CAH) remains difficult, and clinical practice varies substantiallythroughout the world. To consider the evidence for bestpractice, to formulate management guidelines, and to considerinnovative therapies, The Lawson Wilkins PediatricEndocrine Society (LWPES) and The European Society forPediatric Endocrinology (ESPE) convened a meeting inGloucester, MA, March 14–17, 2002. The 40 participatingphysicians, psychologists, scientists, and surgeons from 12countries on 4 continents agreed with the following consensusstatement; this statement is concerned exclusively withCAH caused by 21-hydroxylase deficiency and does not addressthe other, rarer forms of CAH.
đang được dịch, vui lòng đợi..